title: Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
abstract: Tumor-derived autophagosomes (DRibble) selectively capture tumor-specific antigens and induce a dramatic T-cell activation and expansion when injected into lymph nodes of naive mice. Both dendritic and B cells can efficiently cross-prime antigen-specific T cells. In this report, we demonstrated that a booster vaccination with naive B cells loaded with DRibbles eradicated E.G7-OVA tumors in mice that were previously treated with adoptive transfer naive OT-I T cells and intranodal immunization with DRibbles derived from E.G7 tumors. The antitumor efficacy was accompanied by a heighten number of tumor-specific interferon-γ-producing T cells and antibodies. However, the same treatment in the absence of adoptive T-cell transfer exhibited a limited efficacy. In contrast, when DRibble-loaded B cells were activated with CpG and anti-CD40 antibody before use as booster vaccines, established E.G7 tumors were completely eradicated in the absence of T-cell transfer. Therefore, our results document that B cells could efficiently cross-present tumor-specific antigens captured by DRibbles and suggest that naive B cells can be deployed as an effective and readily accessible source of antigen-presenting cells for cancer immunotherapy clinical trials.
authors.affiliation: *Department of Microbiology and Immunology, Medical School of Southeast University †Cancer Research and Biotherapy Center, the Second Affiliated Hospital of Southeast University, Nanjing, Jiangsu Province, People's Republic of China ‡Laboratory of Cancer Immunobiology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Ren
authors.forename: Simin
authors.initials: S
authors.lastname: Zhao
authors.forename: Weixia
authors.initials: W
authors.lastname: Li
authors.forename: Huixia
authors.initials: H
authors.lastname: Dong
authors.forename: Meng
authors.initials: M
authors.lastname: Zhou
authors.forename: Meng
authors.initials: M
authors.lastname: Cao
authors.forename: Hong-Ming
authors.initials: HM
authors.lastname: Hu
authors.forename: Li-xin
authors.initials: LX
authors.lastname: Wang
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001343:Autophagy / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D019013:CD40 Antigens / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045142:Cross-Priming; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009838:Oligodeoxyribonucleotides / Q000276:immunology; D010588:Phagosomes / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D047368:Tumor Burden
chemical_list: D000951:Antigens, Neoplasm; D019013:CD40 Antigens; D019496:Cancer Vaccines; D009838:Oligodeoxyribonucleotides; D007371:Interferon-gamma